Adcendo – Data Presentation on uPARAP targeting ADCs in Osteosarcoma PDX Models at the 2022 AACR Annual Meeting

Copenhagen, Denmark, April 11th, 2022 – Adcendo ApS (“Adcendo”), a biotech company focused on
the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved
cancers, is pleased to announce that a poster presentation will be provided on data of uPARAP
targeting Antibody-Drug Conjugates in osteosarcoma preclinical xenograft models at the ongoing
American Association for Cancer Research (AACR) Annual Meeting, held in New Orleans from April 8-
13, 2022.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...